MX2009004699A - Compuestos de piridinona. - Google Patents
Compuestos de piridinona.Info
- Publication number
- MX2009004699A MX2009004699A MX2009004699A MX2009004699A MX2009004699A MX 2009004699 A MX2009004699 A MX 2009004699A MX 2009004699 A MX2009004699 A MX 2009004699A MX 2009004699 A MX2009004699 A MX 2009004699A MX 2009004699 A MX2009004699 A MX 2009004699A
- Authority
- MX
- Mexico
- Prior art keywords
- pyridinone compounds
- compound
- directed
- pyridinone
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La invención se dirige a compuestos de piridinona útiles para modular la cinasa Met que tiene la siguiente estructura: (ver fórmula (I)) y se dirige además a composiciones farmacéuticas que comprenden el compuesto; y métodos para tratar enfermedades proliferativas, tales como cáncer por la administración de este compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85754006P | 2006-11-08 | 2006-11-08 | |
PCT/US2007/084047 WO2008058229A1 (en) | 2006-11-08 | 2007-11-08 | Pyridinone compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004699A true MX2009004699A (es) | 2009-05-15 |
Family
ID=39048786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004699A MX2009004699A (es) | 2006-11-08 | 2007-11-08 | Compuestos de piridinona. |
Country Status (21)
Country | Link |
---|---|
US (2) | US7851489B2 (es) |
EP (1) | EP2089364B1 (es) |
JP (1) | JP5276005B2 (es) |
KR (1) | KR101390076B1 (es) |
CN (1) | CN101535264B (es) |
AR (1) | AR063628A1 (es) |
AU (1) | AU2007317296B2 (es) |
CA (1) | CA2669266C (es) |
CL (1) | CL2007003226A1 (es) |
DK (1) | DK2089364T3 (es) |
ES (1) | ES2424851T3 (es) |
HK (1) | HK1131608A1 (es) |
HR (1) | HRP20130626T1 (es) |
MX (1) | MX2009004699A (es) |
NO (1) | NO342395B1 (es) |
PE (1) | PE20081490A1 (es) |
PL (1) | PL2089364T3 (es) |
PT (1) | PT2089364E (es) |
SI (1) | SI2089364T1 (es) |
TW (1) | TWI409259B (es) |
WO (1) | WO2008058229A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101977905B (zh) | 2008-01-23 | 2014-07-02 | 百时美施贵宝公司 | 4-吡啶酮化合物及其对于癌症的用途 |
EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
WO2011139891A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
ES2533075T3 (es) * | 2010-04-30 | 2015-04-07 | Bristol-Myers Squibb Company | Composiciones farmacéuticas que comprenden N-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4-etoxi-1-(4-fluorofenil)-2-oxo-1,2-dihidropiridin-3-carboxamida |
CN102241625B (zh) * | 2010-05-13 | 2014-10-29 | 中南大学 | 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途 |
CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
HUE059230T2 (hu) * | 2011-06-10 | 2022-10-28 | Merck Patent Gmbh | Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására |
BR112014012407A2 (pt) * | 2011-11-22 | 2017-06-06 | Deciphera Pharmaceuticals Llc | amidas de piridona e análogos exibindo propriedades anti-câncer e anti-proliferativas |
AU2013296897B2 (en) | 2012-07-28 | 2015-09-17 | Beijing Findcure Biosciences Ltd. | Substituted pyrazolone compounds and methods of use |
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP4141002A1 (en) | 2015-11-19 | 2023-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PL3394033T3 (pl) | 2015-12-22 | 2021-05-31 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
MX2018016273A (es) | 2016-06-20 | 2019-07-04 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
EP3484866B1 (en) * | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
ES2891527T3 (es) * | 2016-12-19 | 2022-01-28 | Novartis Ag | Nuevos derivados de ácido picolínico y su uso como intermedios |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
CN110582493B (zh) | 2016-12-22 | 2024-03-08 | 因赛特公司 | 作为免疫调节剂的苯并噁唑衍生物 |
WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
WO2018160138A1 (en) | 2017-03-02 | 2018-09-07 | Aslan Pharmaceuticals Pte Ltd | Dhodh inhibitor for treating haematological cancer |
CN108623568B (zh) * | 2017-03-21 | 2022-04-19 | 南京汇诚制药有限公司 | 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备 |
WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2019083455A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS |
WO2019083457A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY |
WO2019083458A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA |
WO2019083456A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS |
US11623923B2 (en) | 2017-11-24 | 2023-04-11 | Medshine Discovery, Inc. | Uracil compound as c-MET/AXL inhibitor |
BR112020008663A2 (pt) | 2018-03-08 | 2020-10-06 | Wellmarker Bio Co., Ltd. | composto derivado de tienopiridina, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo |
DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
KR20210090625A (ko) | 2018-10-09 | 2021-07-20 | 아슬란 파마슈티컬스 피티이 엘티디 | 바를리티닙의 말론산 염 |
US20210379077A1 (en) * | 2018-10-19 | 2021-12-09 | The University Of British Columbia | Topoisomerase ii catalytic inhibitor compound therapeutics for cancer treatment, methods and uses |
EP3911320A4 (en) * | 2019-01-15 | 2022-11-30 | The Translational Genomics Research Institute | PHOSPHONATE CONJUGATES AND USES THEREOF |
WO2021025407A1 (ko) | 2019-08-02 | 2021-02-11 | 웰마커바이오 주식회사 | 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물 |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
EP3819300A4 (en) | 2019-09-06 | 2021-11-24 | Wellmarker Bio Co., Ltd. | THERAPEUTIC COMPOSITION BASED ON BIOMARKERS |
TW202120504A (zh) | 2019-11-11 | 2021-06-01 | 美商英塞特公司 | Pd-1/pd-l1 抑制劑之鹽及結晶型 |
KR20210100557A (ko) | 2020-02-06 | 2021-08-17 | 웰마커바이오 주식회사 | Kras 돌연변이와 관련된 암의 예방 또는 치료용 약학 조성물 |
WO2021177721A1 (ko) | 2020-03-03 | 2021-09-10 | 웰마커바이오 주식회사 | Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물 |
KR20210142553A (ko) | 2020-05-18 | 2021-11-25 | 웰마커바이오 주식회사 | Ron 돌연변이와 관련된 소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법 |
US20230242521A1 (en) | 2020-05-18 | 2023-08-03 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same |
JP2023526443A (ja) | 2020-05-18 | 2023-06-21 | ウェルマーカー バイオ カンパニー リミテッド | Ron変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
EP4332106A1 (en) * | 2021-06-22 | 2024-03-06 | LG Chem, Ltd. | Novel compound as protein kinase inhibitor |
US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0430885A3 (en) | 1989-12-01 | 1991-11-06 | Ciba-Geigy Ag | Anthelmintical compounds |
WO1997017329A1 (fr) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
US6429213B1 (en) | 1998-06-17 | 2002-08-06 | Bristol Myers Squibb Pharma Co | Cyclic hydroxamic acids as metalloproteinase inhibitors |
KR100743262B1 (ko) | 1999-07-20 | 2007-07-27 | 다우 아그로사이언시즈 엘엘씨 | 살균성 헤테로고리 방향족 아미드 및 그 조성물, 사용 및제조방법 |
US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
RU2002110461A (ru) | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
SE0102384D0 (sv) | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
AU2002344567A1 (en) | 2001-11-28 | 2003-06-10 | Daiso Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
JP4829506B2 (ja) | 2004-02-17 | 2011-12-07 | 石原産業株式会社 | チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
AU2005245386B2 (en) | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2007
- 2007-11-08 AU AU2007317296A patent/AU2007317296B2/en active Active
- 2007-11-08 KR KR1020097009449A patent/KR101390076B1/ko active IP Right Grant
- 2007-11-08 US US11/936,984 patent/US7851489B2/en active Active
- 2007-11-08 EP EP07844974.1A patent/EP2089364B1/en active Active
- 2007-11-08 PE PE2007001538A patent/PE20081490A1/es active IP Right Grant
- 2007-11-08 DK DK07844974.1T patent/DK2089364T3/da active
- 2007-11-08 WO PCT/US2007/084047 patent/WO2008058229A1/en active Application Filing
- 2007-11-08 AR ARP070104987A patent/AR063628A1/es active Pending
- 2007-11-08 CN CN2007800414202A patent/CN101535264B/zh active Active
- 2007-11-08 MX MX2009004699A patent/MX2009004699A/es active IP Right Grant
- 2007-11-08 PT PT78449741T patent/PT2089364E/pt unknown
- 2007-11-08 CL CL200703226A patent/CL2007003226A1/es unknown
- 2007-11-08 PL PL07844974T patent/PL2089364T3/pl unknown
- 2007-11-08 SI SI200731303T patent/SI2089364T1/sl unknown
- 2007-11-08 ES ES07844974T patent/ES2424851T3/es active Active
- 2007-11-08 CA CA2669266A patent/CA2669266C/en active Active
- 2007-11-08 TW TW096142253A patent/TWI409259B/zh active
- 2007-11-08 JP JP2009536476A patent/JP5276005B2/ja active Active
-
2009
- 2009-04-22 NO NO20091605A patent/NO342395B1/no unknown
- 2009-11-02 HK HK09110170.2A patent/HK1131608A1/xx unknown
-
2010
- 2010-11-08 US US12/941,419 patent/US8536200B2/en active Active
-
2013
- 2013-07-03 HR HRP20130626TT patent/HRP20130626T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US8536200B2 (en) | 2013-09-17 |
CN101535264A (zh) | 2009-09-16 |
US20110052583A1 (en) | 2011-03-03 |
US7851489B2 (en) | 2010-12-14 |
JP2010509362A (ja) | 2010-03-25 |
NO20091605L (no) | 2009-05-27 |
SI2089364T1 (sl) | 2013-10-30 |
TW200829564A (en) | 2008-07-16 |
PE20081490A1 (es) | 2008-10-30 |
HRP20130626T1 (en) | 2013-08-31 |
NO342395B1 (no) | 2018-05-14 |
CA2669266C (en) | 2014-04-29 |
CA2669266A1 (en) | 2008-05-15 |
WO2008058229A1 (en) | 2008-05-15 |
PL2089364T3 (pl) | 2013-11-29 |
JP5276005B2 (ja) | 2013-08-28 |
CN101535264B (zh) | 2012-11-28 |
AU2007317296A1 (en) | 2008-05-15 |
AR063628A1 (es) | 2009-02-04 |
ES2424851T3 (es) | 2013-10-09 |
US20080114033A1 (en) | 2008-05-15 |
TWI409259B (zh) | 2013-09-21 |
PT2089364E (pt) | 2013-08-26 |
CL2007003226A1 (es) | 2008-02-08 |
KR101390076B1 (ko) | 2014-04-29 |
EP2089364B1 (en) | 2013-06-12 |
EP2089364A1 (en) | 2009-08-19 |
DK2089364T3 (da) | 2013-09-02 |
HK1131608A1 (en) | 2010-01-29 |
KR20090096423A (ko) | 2009-09-10 |
AU2007317296B2 (en) | 2012-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009004699A (es) | Compuestos de piridinona. | |
UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
GEP20135925B (en) | Inhibitors of hedgehog pathway | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
GEP20166484B (en) | Protein kinase inhibitors | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
EP3483143A8 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
WO2008064018A8 (en) | Thienopyrimidinones for treatment of inflammatory disorders and cancers | |
NZ577916A (en) | Cyclopamine analogs | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
MX2009011816A (es) | Derivados de piridina. | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
UA94749C2 (en) | Benzimidazole modulators of vr1 | |
AU2009282962A8 (en) | Compounds as kinase inhibitors | |
WO2008013987A3 (en) | N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
DK1885187T3 (da) | Fremgangsmåde til behandling af lægemiddelresistent cancer | |
MX2012015100A (es) | Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |